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Abstract: Background: Carbapenems (ertapenem, imipenem, meropenem) are used to treat multidrug-
resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB), even if the published evidence
is limited, particularly when it is otherwise difficult to identify the recommended four active drugs
to be included in the regimen. No systematic review to date has ever evaluated the efficacy, safety,
and tolerability of carbapenems. Methods: A search of peer-reviewed, scientific evidence was carried
out, aimed at evaluating the efficacy/effectiveness, safety, and tolerability of carbapenem-containing
regimens in individuals with pulmonary/extra-pulmonary disease which was bacteriologically
confirmed as M/XDR-TB. We used PubMed to identify relevant full-text, English manuscripts up to
the 20 December 2015, excluding editorials and reviews. Results: Seven out of 160 studies satisfied
the inclusion criteria: two on ertapenem, one on imipenem, and four on meropenem, all published
between 2005 and 2016. Of seven studies, six were retrospective, four were performed in a single
center, two enrolled children, two had a control group, and six reported a proportion of XDR-TB cases
higher than 20%. Treatment success was higher than 57% in five studies with culture conversion rates
between 60% and 94.8%. Conclusions: The safety and tolerability is very good, with the proportion
of adverse events attributable to carbapenems below 15%.
Keywords: MDR-TB; XDR-TB; carbapenems; imipenem; meropenem; ertapenem; effectiveness;
safety; tolerability
1. Introduction
With over 480,000 new multidrug-resistant tuberculosis (MDR-TB, i.e., tuberculosis caused
by Mycobacterium tuberculosis strains resistant, in vitro, to at least isoniazid and rifampicin) cases
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and 190,000 deaths estimated to have occurred in 2014 by the World Health Organization (WHO),
tuberculosis is a global clinical and public health priority [1].
Our capacity to diagnose MDR-TB cases remains limited (one in three) and that of treating them
even lower (one in four) [1].
Half of the 123,000 cases of MDR-TB reported by WHO in 2014 occurred in India, the Russian
Federation, and South Africa. As of today 3.3% among the new TB cases (e.g., those never treated
for TB for more than 30 days) and 20% of the previously-treated TB cases harbor MDR-TB strains
of Mycobacterium tuberculosis. Unfortunately, about 10% of these strains meet the criteria defining
extensively drug resistant TB (XDR-TB), e.g., additional resistance to at least one fluoroquinolone and
a second line-injectable drug (amikacin, capreomycin, and kanamycin). In some countries belonging
to of the former Soviet Union, MDR-TB hot spots exist, with reported prevalence as high as 29% in
Belarus, 15% in Latvia, and 15% in Georgia [1,2].
As clinicians managing MDR- and XDR-TB patients in reference centers perfectly know, treating
these cases is long, expensive, and complicated, and a wealth of experience in managing adverse
events (which are frequent) is necessary [3–8].
WHO recommends the design of effective background regimens for MDR- and XDR-TB using
a stepwise approach: active second-line drugs (based on the drug susceptibility test-DST) need to
be introduced according to an order of priority based on their efficacy and safety. To simplify the
procedure these drugs are classified into five groups based on a hierarchical order [7,9].
The core issue facing clinicians, is the difficulty in identifying at least four active drugs which are
necessary to design an effective multi-drug regimen as per WHO guidelines [3,4,7,10,11].
When MDR-TB cases with resistance patterns “beyond XDR” have to be managed [3] new drugs
(like delamanid [12–14] and bedaquiline [15–20]), and several re-purposed drugs, need to be taken
into consideration [7,21].
Within the WHO Group 5, i.e., drugs with unknown/limited evidence on efficacy and/or
tolerability, linezolid [10,22–28], and carbapenems [29–34] are often used for this purpose.
Although as of today carbapenems (which include meropenem, imipenem, and ertapenem) are
presently prescribed to manage M/XDR-TB cases, the evidence on their efficacy, safety, and tolerability
is anecdotal [29–43].
The aim of this systematic review is to describe the therapeutic contribution, effectiveness, safety,
and tolerability profile of the carbapenems (meropenem, imipenem, and ertapenem) added to a
background regimen in the treatment of MDR- and XDR-TB cases.
2. Methods
A search of peer-reviewed, scientific evidence was carried out, aimed at evaluating the efficacy/
effectiveness, safety, and tolerability of carbapenem-containing regimens in individuals with a
pulmonary/extra-pulmonary disease, which was culture- and DST-confirmed as M/XDR-TB.
We used the database PubMed to identify any relevant full-text English manuscript without any
time constraints until 20 December 2015. We decided to exclude conferences’ abstracts because, on the
basis of the word count, the information provided is too limited when assessing the above described
objectives. A search for ongoing or recently completed trials on clinicaltrials.gov was also performed.
Several key-words (i.e., MDR-TB, XDR-TB, efficacy, effectiveness, safety, tolerability, carbapenem,
meropenem, imipenem, ertapenem) were identified by the authors and combined to create ad hoc
strings to retrieve the most relevant scientific articles. References’ lists of the selected papers were
analyzed in order to identify articles missed by the adopted search algorithms.
The search exclusion criteria were the following:
(1) Case-reports describing fewer than 3 M/XDR-TB cases;
(2) Experimental studies on animals with TB;
(3) Reviews and editorials on carbapenems and M/XDR-TB; and
(4) Unclear/unconfirmed M/XDR-TB diagnosis of treated patients.
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The carbapenems considered for the present review were the following: imipenem, meropenem,
and ertapenem (there is no published data on the in vivo use of doripenem, biapenem, panipenem,
and faropenem in TB patients). Observational and experimental studies were considered suitable for
the estimation of the efficacy/effectiveness, safety, and tolerability of the carbapenems.
Several demographic, epidemiological, clinical variables were collected: epidemiological
design of the study, age and sex of the enrolled patients, duration of the study, location/s of the
study (mono/multi-center, university/reference/peripheral hospital, country/ies), number and
characteristics of treated M/XDR-TB patients, number and characteristics of control cases if any,
dosage and duration of the administered drugs, adverse events and their severity if any, treatment
outcomes recorded according to the WHO classification [44], sputum smear, and culture conversion.
Two authors independently performed the search and evaluated the titles and abstracts of the
records according to the selection criteria. Potentially interesting articles were downloaded and
critically assessed; when they satisfied the inclusion criteria, the planned information was retrieved
and collected using a pre-designed electronic template. The entire process was carried out following
the guidelines of the 2009 Preferred Reporting Items for Systematic Reviews and Meta-Analysis [45].
3. Results
A total of 159 records were obtained from the search. Nine studies satisfied the inclusion criteria
and were deemed appropriate for a qualitative analysis. The entire selection process is summarized
in the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart
(Figure 1).
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Two (22.2%) studies were focused on ertapenem [31,32], five (55.5%) on meropenem [29,30,40,41,43],
and two (22.2%) on imipenem [33,42]. The majority of the studies were performed in Europe [29–32]
(four, 66.7%), one (16.7%) in South [40] and one (16.7%) in North America [33], and three in Europe
and South America [41–43] (Table 1).
Table 1. Epidemiological characteristics of the selected studies.
First Author PublicationYear Country Study Design Clinical Setting
Study
Duration
Chambers H.F. [33] 2005 USA Prospective
Monocenter,
university clinical
research center in
collaboration with a
general hospital
ND
Palmero D. [40] 2015 Argentina Retrospective
Monocenter,
university
medical centre
2012–2013
De Lorenzo S. [29] 2013 Italy, The Netherlands Retrospective,case-control
Multicenter,
university medical
center and
general hospital
2001–2012
van Rijn S.P. [32] 2016 The Netherlands Retrospective
Monocenter,
university
medical center
2010–2013
Tiberi S. [31] 2016 Italy, The Netherlands Retrospective
Multicenter,
university medical
center and
general hospital
2008–2015
Tiberi S. [41] 2016
Italy, The Netherlands,
Belgium, United Kingdom,
Greece, Peru, Brazil, Spain,
France, Ecuador,
Belarus, Slovakia
Retrospective,
cohort
Multicenter,
university medical
centers and
general hospitals
2003–2015
Payen M.C. [30] 2012 Belgium Retrospective
Monocenter,
university
medical centre
2009–ND
Tiberi S. [42] 2016
Italy, The Netherlands,
Belgium, United Kingdom,
Greece, Peru, Brazil, Spain,
France, Ecuador,
Belarus, Slovakia
Retrospective,
cohort
Multicenter,
university medical
centers and
general hospitals
2003–2015
Tiberi S. [43] * 2016
Italy, The Netherlands,
Belgium, United Kingdom,
Greece, Peru, Brazil, Spain,
France, Ecuador,
Belarus, Slovakia
Retrospective,
cohort
Multicenter,
university medical
centers and
general hospitals
2005–2015
ND: Not Declared: * Cohorts enrolled in the studies [41,42].
The studies were published (or are in press) between 2005 and 2016 [29–33,40–43]. The
epidemiological design of the studies was retrospective in eight out of nine [29–32,40–43] (88.9%)
and about 50% of them (4/9) were carried out in a single medical center [30,32,33,40]. No clinical trials
were performed.
Patients were recruited and exposed to carbapenems from 2001 [29] to 2015 [31,41–43]. The
mean number of patients exposed to single carbapenems were 44.6 per study, ranging from five [31]
to 96 [41,43]. Only two studies enrolled children [30,32], and three studies included a control
group [29,41,42]. The proportion of XDR-TB cases was higher than 20% in all but one study [32]
(Table 2).
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Table 2. Clinical features of the selected studies.
First Author
Individuals
Exposed to
Carbapenems
Paediatric
Patients
Control
Group
XDR-TB
Cases (%)
Carbapenem
Administered
Carbapenem
Dosage
Chambers H.F.
[33] 10 No No 2/10 (20.0) Imipenem 1 g bid
Palmero D. [40] 10 No No 4/10 (40.0) Meropenem 2 g tid,then 2 g tid
De Lorenzo S. [29] 37 No Yes 9/37 (24.3) Meropenem 1 g tid
Van Rijn S.P. [32] 18 Yes; ND No ND Ertapenem 1 g qd
Tiberi S. [31] 5 No No 2/5 (40.0) Ertapenem 1 g qd
Tiberi S. [41] 96 No Yes 47/96 (49.0) Meropenem 1 g tid (2 g tid inBelgium)
Payen M.C. [30] 6 1/6 No 6/6 (100.0) Meropenem 2 g tid,then 2 g bid
Tiberi S. [42] 84 No Yes 57/84 (67.9) Imipenem 500 mg qid
Tiberi S. [43] * 84 Imipenem96 Meropenem No No
57/84 (67.9)
Imipenem
47/96 (49.0)
Meropenem
Imipenem
Meropenem
Imipenem:
500 mg qid
Meropenem:
1 g tid (2 g tid
in Belgium)
qd: once a day; bid: twice a day; tid: thrice a day; qid: quarter: four times a day; ND: not declared; XDR_TB:
extensively drug-resistant tuberculosis; * Cohorts enrolled in the studies [41,42].
Daily dosages of meropenem varied in the selected studies; however, all the individuals with
MDR-TB exposed to ertapenem were administered a single daily dose of 1 g [31,32].
Overall, the efficacy/effectiveness profile of the carbapenems was positive. Treatment success was
higher than 50% in seven studies [31–33,40–43], up to 80% in patients exposed to ertapenem-containing
regimens [31,32] (Table 3). In particular, culture conversion rates ranged from 60.0% [31] to 94.8% [41].
Safety and tolerability was very good, with the proportion of adverse events attributable to carbapenems
below 15%.
Table 3. Effectiveness, safety, and tolerability profiles of carbapenems in the selected studies.
First Author Sputum SmearConversion (%)
Sputum Culture
Conversion (%)
Treatment
Success (%) **
Adverse events
Attributed to
Carbapenems (%)
Interruption of
Carbapenems Due to
Adverse Events (%)
Chambers H.F. [33] ND 7/9 (77.8) 7/10 (70.0) ND ND
Palmero D. [40] ND 8/10 (80.0) 3/6 (50.0) 0/10 (0.0) ND
De Lorenzo S. [29] 28/32 (87.5) 31/37 (83.8) ND 5/37 (13.5) 2/5 (40.0)
van Rijn S.P. [32] ND 15/18 (83.3) 15/18 (83.3) 2/18 (11.1) 3/18 (16.7)
Tiberi S. [31] 3/5 (60.0) 3/5 (60.0) 4/5 (80.0) 0/5 (0.0) 2/5 (40.0)
Tiberi S. [41] 55/58 (94.8) 55/58 (94.8) 55/96 (57.3) 6/93 (6.5) 8/94 (8.5)
Payen M.C. [30] 5/6 (83.3) 5/6 (83.3) ND 0/6 (0.0) 0/6 (0.0)
Tiberi S. [42] 51/64 (79.7) 46/64 (71.9) 34/57 (59.7) 3/56 (5.4) 4/55 (7.3)
Tiberi S. [43] *
Imipenem
51/64 (79.7)
Meropenem
55/58 (94.8)
Imipenem
46/64 (71.9)
Meropenem
55/58 (94.8)
Imipenem
34/57 (59.7)
Meropenem
55/71 (77.5)
Imipenem
3/56 (5.4)
Meropenem
6/93 (6.5)
Imipenem
4/55 (7.3)
Meropenem
8/94 (8.5)
ND: Not Declared: * Cohorts enrolled in the studies [41,42]; ** Definition of treatment success was that provided
by the authors when available.
4. Discussion
Aim of this systematic review is to describe the effectiveness, safety, and tolerability profile of
carbapenems added to a background regimen, in the treatment of MDR- and XDR-TB cases.
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Overall, the results of the systematic review show that carbapenems are safe and likely to be
effective in treating M/XDR-TB.
Although not all the studies reported sputum smear and culture conversions rates, the available
information confirms that the treatment outcomes of the cohorts treated with carbapenems was in
general better than those reported in the literature [3,4,46].
In the largest cohort of MDR-TB cases available in the literature (almost 10,000 cases) the treatment
success in the whole cohort was slightly higher than 60%, being much lower in XDR-TB cases: 43% in
those meeting strictly the definition (e.g., being resistant to at least one fluoroquinolone and one
second-line injectable drug), 30% among those with resistance to two second-line injectables and as
low as 19% among those with additional resistance to ethambutol and pyrazinamide. In the cohorts
in which carbapenems were used the treatment success ranged from 57.3% to 80.3% (although the
definition was not standardized for the selected studies), and the culture conversion rates (which are
considered predictors of success) ranged from 60% to almost 95%.
As recently shown [46], high sputum smear and culture conversion rates are likely to indicate low
probability of acquiring drug resistance.
This systematic review highlights the observational nature of the studies performed to date.
In the majority of the cases the authors of the selected studies carried out a description of case-series,
excluding a control group from the epidemiological design. Furthermore, sample sizes were frequently
small, on the basis of being mono-center studies and being performed in areas of low M/XDR-TB
prevalence. All the studies were focused on difficult-to-treat cases. Evidence on children is limited and
deserves further investigation, as well as a more accurate detailed profile on the safety and tolerability
profile of the prescribed drugs. In particular, it would be important to assess the causal relationship
between the occurrence of an adverse event and a specific drug. The majority of the papers we
retrieved do not follow an international, standardized approach for the classification of adverse events,
being more focused on effectiveness.
Another important topic which should be better analyzed by future studies is the patients’
adherence to the prescribed drugs. No relevant information was provided by the studies included in
this systematic review.
One of the most interesting findings is represented by the high effectiveness in cohorts of patients
where the number of XDR-TB cases is high. It is clear that these preliminary results should be confirmed
in order to better understand how and in which patient categories the carbapenem-containing regimens
may make a difference.
Consecutive enrolment, missing blindness, and treatment randomization represent relevant
methodological biases which may hamper the inference of the findings of the available studies.
However, this review summarizes the current scientific evidence, highlighting the shortcomings which
could be improved in the near future. In particular, more emphasis should be given to regimens
including meropenem and ertapenem.
Unfortunately, it was not possible to perform a meta-analysis. Data collected and summarized
from the authors of the selected papers were heterogeneous and not sufficient to carry out a quantitative
analysis. Moreover, only a few papers described the clinical activity of the three single molecules,
including five on meropenem, two on ertapenem, and three focused on imipenem. Likely, the authors
did not compute the necessary sample size to reduce the β error and to increase the statistical power
of the study. All the methodological limitations have undoubtedly reduced the reliability of the
clinical findings.
Randomized, controlled clinical trials should be implemented in order to elucidate the real
therapeutic contribution of carbapenems in TB treatment success; different anti-TB regimens, as well
as the different duration of the carbapenem’s exposure, can create background noise which can hinder
the interpretation of the carbapenem’s contribution. The experimental studies should be based on the
comparisons between the different carbapenems, as well as between the carbapenem and the current
therapeutic alternatives. The investigators should consider all the demographic, epidemiological,
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microbiologic, and clinical characteristics, including the number of resistances to anti-TB drugs, which
could influence the real impact of the pharmacodynamic action of the carbapenems. Furthermore,
drug-drug interactions of carbapenems with the new anti-TB drugs bedaquiline and delamanid in
terms of reduced/increased efficacy and safety should be investigated.
Of interest, there are two recent early bactericidal activity trials (phase-two trials) testing
carbapenems; one trial evaluates the early bactericidal activity, safety, and tolerability of meropenem
plus amoxycillin/CA and faropenem plus amoxycillin/CA in adult patients with newly-diagnosed
pulmonary tuberculosis (NCT02349841) has recently been completed (results awaiting).
The second trial evaluating the early bactericidal activity study of faropenem (with amoxicillin/
clavulanic acid) in patients with pulmonary tuberculosis is currently recruiting (NCT02381470). These
two phase-two trials will be of interest as they will be able to evaluate the individual bactericidal
contribution of the penem/carbapenem drugs [47].
Economic analysis studies will also provide a proper perspective of the future role of carbapenems
in the treatment armamentarium. The identification of new and more effective therapeutic strategies is
crucial to reduce the increasing clinical, economic, and financial burden associated to the emergence of
the MDR-TB epidemic, particularly in low- and middle-income countries (e.g., Southeast Asia and
former Soviet Union countries) [48].
5. Conclusions
The systematic review is a contribution toward the best possible use of carbapenems when the
number of active drugs necessary to design an effective regimen is lacking [3,4,9,49].
Although new drugs are becoming available to support the move towards TB elimination [50–54],
repurposed drugs, like the carbapenems, exemplified by their tolerability, safety, and activity show a
potential role in the TB treatment arena, and could be included in new TB drug combination trials,
as better evidence is needed.
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